| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other (expense) income, net | -17,873 | -12,825 | 9,830 | -5,761 |
| Loss before income taxes | -33,093 | -37,212 | -23,426 | -32,044 |
| Income tax provision | 34 | 40 | 36 | 28 |
| Net loss | -33,127 | -37,252 | -23,462 | -32,072 |
| Basic net income (loss) per common share ( a / b) | -3.82 | -4.32 | -2.77 | -0.26 |
| Earnings per share, diluted, total | -3.82 | -4.32 | -2.77 | -0.26 |
| Weighted average number of shares outstanding, basic | 8,669 | 8,620 | 8,470 | 125,010 |
| Weighted-average number of common shares outstanding used to compute diluted net loss per share | 8,669 | 8,620 | 8,470 | 125,010 |
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)